Strategic Partnership Hemotek is collaborating with Baylor on Ox66, indicating established academic and clinical interest that can be leveraged to co-market oxygenated therapeutics and explore joint development or licensing opportunities with hospitals and research institutions.

Regulatory Readiness With Ox66 currently in the pre-approval stage and active commercialization with several commercial customers, there is a clear pathway to expand pilot programs, gain FDA dialogue support, and accelerate clinical evidence generation to shorten time to market.

Diversified Customer Base The product has already been sold to multiple commercial customers, suggesting opportunities to upsell to additional healthcare providers, clinics, and oxygen therapy distributors, as well as potential for expansion into international markets pending regulatory clearance.

Clinical Advantage Ox66 is a soluble, non-gaseous oxygen powder, a unique modality that can differentiate Hemotek’s offerings in oxygen therapy and potentially open doors with pharma, medical device firms, and specialty care networks seeking novel oxygenation solutions.

Financial Growth Reported revenue in the range of one to ten million positions Hemotek as a qualifying target for mid-size healthcare suppliers and distributors, presenting opportunities for channel partnerships, co-marketing, and value-based procurement discussions.